# EDGAR Filing Document

**Accession Number:** 0001979005
**File Stem:** 0000000000-25-007988
**Filing Date:** 2025-7
**Character Count:** 3317
**Document Hash:** 46d55133469c148948d0f9d2a69d9dfd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007988.hdr.sgml**: 20251203

**ACCESSION NUMBER**: 0000000000-25-007988

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250730

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aimei Health Technology Co., Ltd.
- **CENTRAL INDEX KEY:** 0001979005
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-41880

**BUSINESS ADDRESS:**
- **STREET 1:** 10 EAST 53RD STREET
- **STREET 2:** SUITE 3001
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 34 678 035200

**MAIL ADDRESS:**
- **STREET 1:** 10 EAST 53RD STREET
- **STREET 2:** SUITE 3001
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001641172-25-001169

## Text-Extract

```

                                                           July 30, 2025

Junheng Xie
Chief Executive Officer and Director
Aimei Health Technology Co., Ltd.
10 East 53rd Street, Suite 3001
New York, NY 10022

       Re: Aimei Health Technology Co., Ltd.
           Form 10-K for the Fiscal Year Ended December 31, 2024
           File No. 001-41880
Dear Junheng Xie:

       We have reviewed your filing and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 10-K for the Fiscal Year Ended December 31, 2024
General

1.     Please confirm that you will revise future filings, as applicable, to
provide more
       specific and prominent disclosures about the legal and operational risks
associated
       with China-based companies. For additional guidance, please see the
Division of
       Corporation Finance's Sample Letter to China-Based Companies issued by
the Staff in
       December 2021. To the extent the Sample Letter to China-Based Companies
requests
       disclosure on the prospectus cover page or in the prospectus summary,
please provide
       such disclosure at the beginning of Item 1 of Form 10-K; in addition,
please include a
       discussion of the transfer of cash within the company in Item 7 of Form
10-K.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Please contact Eric McPhee at 202-551-3693 or Jennifer Monick at
202-551-3295 if
you have questions regarding comments on the financial statements and related
matters. Please contact Pam Howell at 202-551-3357 or Jeffrey Gabor at
202-551-2544 with
 July 30, 2025
Page 2

any other questions.

                       Sincerely,

                       Division of Corporation Finance
                       Office of Real Estate & Construction

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._